نتایج جستجو برای: bilag index

تعداد نتایج: 396114  

Journal: :Clinical and experimental rheumatology 2014
I Castrejón C Tani M Jolly A Huang M Mosca

This review summarises most currently used indices to assess and monitor patients with systemic lupus erythematosus (SLE) in clinical trials, long-term observational studies, and clinical care. Six SLE disease activity indices include the British Isles Lupus Assessment Group Index (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lu...

Journal: :Annals of the rheumatic diseases 1994
K L Lim K Muir R J Powell

OBJECTIVE To investigate the role of serial measurement of urine neopterin concentration in monitoring the progression of systemic lupus erythematosus (SLE) disease activity scored using the British Isles Lupus Assessment Group (BILAG) index. METHODS We followed prospectively 68 unselected SLE patients for a total of 464 patient months during which 233 separate assessments were carried out. A...

ژورنال: :مجله دانشکده پزشکی اصفهان 0
منصور کریمی فر استادیار روماتولوژی، گروه داخلی، دانشکده ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران زهرا سید بنکدار دانشیار روماتولوژی، گروه داخلی، دانشکده ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران. سیاوش نصیری دستیار، گروه داخلی، دانشکده ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

مقدمه: لوپوس اریتماتوس سیستمیک یک بیماری التهابی با علت ناشناخته است که می تواند ارگان های مختلف بدن را درگیر نماید. با توجه به تفاوت هایی که چهره ی بیماری در اجتماعات مختلف دارد، بر آن شدیم تا بیماران لوپوس شهر اصفهان را مورد مطالعه قرار دهیم. روش ها: بیماران مبتلا به فرم قطعی بیماری، طی سال های 88-1387 دردرمانگاه روماتولوژی بیمارستان الزهرای (س) اصفهان به روش سرشماری مورد بررسی قرار گرفتند. ا...

Journal: :Arthritis and rheumatism 2009
Tim Y-T Lu Kristine P Ng Geraldine Cambridge Maria J Leandro Jonathan C W Edwards Michael Ehrenstein David A Isenberg

OBJECTIVE To describe the 6-month clinical outcome and the long-term safety profile of B cell depletion therapy (BCDT) in 50 patients with active systemic lupus erythematosus (SLE), who were nonresponsive or poorly responsive to conventional immunosuppression. METHODS All except 4 of 50 patients with active SLE received 1 gm of rituximab, 750 mg of cyclophosphamide, and 100-250 mg of methylpr...

Journal: :Annals of the Rheumatic Diseases 2021

Background: BILAG-2004 Index (BILAG-2004) has undergone construct and criterion validity is used to assess disease activity in SLE. However, its predictive yet be established. Objectives: This study was determine if according of development damage an inception cohort. Methods: a prospective multi-centre longitudinal the UK cohort SLE patients (recruited within 12 months achieving 1997 ACR revis...

2017
Megan E. B. Clowse Daniel J. Wallace Richard A. Furie Michelle A. Petri Marilyn C. Pike Piotr Leszczyński C. Michael Neuwelt Kathryn Hobbs Mauro Keiserman Liliana Duca Kenneth C. Kalunian Catrinel Galateanu Sabine Bongardt Christian Stach Carolyn Beaudot Brian Kilgallen Caroline Gordon A. Batalov M. Bojinca R. Djerassi L. Duca P. Horak Z. Kolarov R. Milasiene D. Monova K. Otsa M. Pileckyte T. Popova F. Radulescu R. Rashkov S. Rednic M. Repin R. Stoilov D. Tegzova N. Vezikova P. Vitek C. Zainea Far East H. Baek Y. Chen Y. Chiu C. Cho C. Chou J. Choe C. Huang Y. Kang S. Kang N. Lai S. Lee W. Park S. Shim C. Suh W. Yoo H. Avila Armengol F. Avila Zapata M. Barreto Santiago F. Cavalcanti W. Chahade L. Costallat M. Keiserman J. Orozco Alcala C. Ramos Remus L. Roimicher M. Abu‐Shakra V. Agarwal N. Agmon‐Levin J. Kadel Y. Levy D. Mevorach D. Paran T. Reitblat I. Rosner V. Shobha Z. Sthoeger D. Zisman K. Ayesu S. Berney J. Box H. Busch J. Buyon J. Carter J. Chi M. Clowse R. Collins K. Dao I. Diab A. Dikranian M. El‐Shahawy N. Gaylis J. Grossman E. Halpert J. Huff W. Jarjour A. Kao R. Katz A. Kennedy M. Khan A. Kivitz M. Kohen T. Lawrence‐Ford J. Lawson M. Levesque M. Lowenstein A. Majjhoo R. Mcarthur D. McLain J. Merrill A. Murillo S. Neucks G. Niemer G. Noaiseh C. Parker C. Pantojas D. Pattanaik M. Petri P. Pickrell J. Reveille A. Roman‐Miranda N. Rothfield A. Sankoorikal M. Sayers A. Singhal A. Snyder C. Striebich Q. Vo J. von Feldt D. Wallace M. Wasko C. Young S. Adelstein S. Hall G. Littlejohn D. Nicholls M. Suranyi Z. Amoura B. Bannert F. Behrens L.Carreno Perez K. Chakravarty F. Diaz Gonzales K. Davies A. Doria P. Emery A. Fernández‐Nebro M. Govoni E. Hachulla B. Hellmich F. Houssiau M. Malaise J. Margaux Y. Maugars S. Muñoz‐Fernández F. Navarro J. Ordi‐Ros R. Pellerito J. Pena‐Sagredo E. Roussou R. E. Schmidt E. Ucar‐Angulo J‐F. Viallard R. Westhovens M. Worm C. S. Yee S. Nayiager H. Reuter C. Spargo B. Bazela M. Brzosko D. Chudzik B. Gasztonyi P. Geher R. Ionescu S. Jeka L. Kemeny E. Kiss P. Kotyla L. Kovacs V. Kovalenko E. Kucharz B. Kwiatkowska P. Leszczynski E. Levchenko G. Lysenko M. Majdan C. Mihailov S. Nalotov M. Nedelciu M. Pavel T. Raskina B. Rebrov E. Rezus T. Semen S. Smakotina M. Stanislavchuk M. Stanislav I. Szombati G. Szucs G. Udrea J. Zajdel A. Zon‐Giebel R. Bonfiglioli R. Bustamante E. Klumb G. Medrano Ramirez C. Neiva M. Olguin J.Reyes Gonzaga A. Scotton S. Sicsik Ayala A. Ximenes R. Sharma C. Srikantiah J. Aelion C. Aranow M. Baker A. Chadha J. Chao W. Chatham A. Chow C. Clay S. Cohen‐Gadol D. Conaway J. Denburg A. Escalante L. Espinoza J. Fiechtner I. Fortin A. Fraser R. Furie D. Gladman D. Goddard M. Goldberg R. Gonzalez‐Rivera J. Gorman R. Griffin D. Haaland D. Halter A. Hemaiden K. Hobbs V. Joshi S. Lim K. Kalunian G. Karpouzas M. Khraishi R. Lafyatis R. Lidman C. Lue M. Mohan P. Mease C. Mehta W. Mizutani A. Nami J. Nascimento C. Neuwelt J. Pappas J. Pope A. Porges G. Roane D. Rosenberg S. Ross C. Saadeh C. Scoville Y. Sherrer M. Solomon W. Surbeck G. Valenzuela P. Waller R. Alten C. Baerwald B. Bienvenu S. Bombardieri J. Braun L. Dival G. Espinosa I. Figueroa Fernandez J. Gomez‐Reino C. Gordon F. Hiepe N. Hopkinson D. Isenberg A. Jacobi C. Jorgensen V. Le Guern C. Paul J. M. Pego‐Reigosa J. Rodriguez Heredia A. Rubbert‐Roth M. Sabbadini J. Schroeder A. Schwarting W. Spieler G. Valesini J. Wollenhaupt A. Zea Mendoza C. Zouboulis

OBJECTIVE Epratuzumab, a monoclonal antibody that targets CD22, modulates B cell signaling without substantial reductions in the number of B cells. The aim of this study was to report the results of 2 phase III multicenter randomized, double-blind, placebo-controlled trials, the EMBODY 1 and EMBODY 2 trials, assessing the efficacy and safety of epratuzumab in patients with moderately to severel...

2009
Christopher Sjöwall Agneta Zickert Thomas Skogh Jonas Wetterö Iva Gunnarsson

INTRODUCTION Serum levels of C-reactive protein (CRP) seldom reflect disease activity in systemic lupus erythematosus (SLE). We have previously shown that autoantibodies against neo-epitopes of CRP often occur in SLE, but that this does not explain the modest CRP response seen in flares. However, we have repeatedly found that anti-CRP levels parallel lupus disease activity, with highest levels ...

2016
Jill Buyon Richard Furie Chaim Putterman Rosalind Ramsey-Goldman Kenneth Kalunian Derren Barken John Conklin Thierry Dervieux

BACKGROUND The relationship between cell-bound complement activation products (CB-CAPs: EC4d, EC3d), anti-C1q, soluble complement C3/C4 and disease activity in systemic lupus erythematosus (SLE) was evaluated. METHODS Per protocol, at baseline all SLE subjects enrolled in this longitudinal study presented with active disease and elevated CB-CAPs. At each monthly visit, the non-serological (ns...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید